ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 136

Prevalence of Rheumatoid Arthritis and Associated Comorbidities in the 2011-2015 Medicare Population

Suying Li, Julia T. Molony, Yi Peng, Kimberly M. Nieman and David T. Gilbertson, Minneapolis Medical Research Foundation, Chronic Disease Research Group, Minneapolis, MN

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: Co-morbidities, liver disease and rheumatoid arthritis (RA), Medicare

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Epidemiology and Public Health Poster I: Rheumatoid Arthritis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease affecting about 1.5 million adults in the US (Helmick et al., 2008). Patients with RA have an increased burden of comorbidity such as cardiovascular disease (CVD), diabetes, cancer, and other inflammatory diseases. This study aimed to update prevalence estimates of RA and associated comorbidity in the US.

Methods: This was a retrospective descriptive study using the 2010-2015 20% Medicare sample data. Yearly prevalent RA cohorts (2011-2015) were defined based on ICD-9 diagnosis code 714.0 with the addition of ICD-10 codes for the 2015 cohort. For each cohort year, included patients were required to have Medicare Part A and Part B coverage with no Medicare Advantage, and to be alive for the entire year preceding a cohort year and through the first month of the cohort year. RA was defined if a diagnosis code was present in at least 1 inpatient claim or 2 or more outpatient claims, separated by at least 30 days. The baseline period was 1 year preceding the cohort year and was used to define comorbidity, including CVD, diabetes, hypertension, hyperlipidemia, cancer, anemia, and other inflammatory conditions such as psoriasis, psoriatic arthritis, non-alcoholic fatty liver disease (NAFLD), and cirrhosis. Prevalence of comorbidity was presented as a percentage of RA patients.

Results: This study included approximately 6 million Medicare beneficiaries in each year, 2011-2015; average RA prevalence was about 2.0% (Table 1). RA patient demographics were similar across years, with mean age 72.4 years; 77.0% were female, 83.4% white, and 10.7% black in the 2015 cohort. Common comorbid conditions in the 2015 RA cohort included hypertension (prevalence 67.3%), hyperlipidemia (48.5%), diabetes (26.6%), anemia (26.4%), arteriosclerotic heart disease (21.5%), peripheral artery disease (17.2%), congestive heart failure (13.2%), and cancer (8.8%) (Table 1). Prevalence of inflammatory conditions increased across years; for example, NAFLD was 0.96% in 2011 and 1.36% in 2015; corresponding values were 0.04% and 0.07% for cirrhosis, 1.14% and 1.45% for psoriasis, and 1.58% and 1.81% for psoriatic arthritis.

Table 1. Prevalence of RA and Associated Comorbid Conditions in 2011-2015 Medicare Patients

Cohort Year

2011

2012

2013

2014

2015

N Medicare patients in the 20% sample

5,845,175

5,859,826

5,906,084

5,975,397

6,324,354

N with RA in the 20% sample

117,014

117,494

118,660

120,448

123,137

% with RA

2.0

2.0

2.0

2.0

2.0

Baseline characteristics in RA patients

Mean age in years (SD)

71.8 (11.6)

71.8 (11.5)

71.7 (11.5)

71.8 (11.4)

72.4 (11.4)

% of Female

75.8

75.9

75.7

75.5

77.0

Race, %

White

82.2

82.3

82.3

82.5

83.4

Black

11.7

11.6

11.5

11.2

10.7

Other

6.1

6.1

6.2

6.3

6.0

Comorbidity (%) in RA patients

Diabetes

26.7

27.2

27.1

27.2

26.6

Hypertension

65.9

66.5

66.6

66.8

67.3

Hyperlipidemia

45.5

47.3

47.8

48.1

48.5

CVD

ASHD

21.9

22.1

21.9

21.6

21.5

CHF

13.2

13.4

13.0

12.8

13.2

CVA/TIA

8.5

8.7

8.6

8.6

8.8

PVD

16.2

16.7

16.4

16.7

17.2

Other cardiac

13.6

14.5

14.0

14.1

14.7

Cancer

8.5

8.8

8.7

8.8

8.8

Anemia

26.8

27.7

27.0

26.7

26.4

GI bleeding

3.2

3.4

3.2

3.2

3.2

Liver

1.76

1.87

1.89

2.03

2.08

NAFLD

0.96

1.05

1.19

1.27

1.36

Cirrhosis

0.04

0.04

0.05

0.05

0.07

Psoriasis

1.14

1.30

1.36

1.43

1.45

Psoriatic arthritis

1.58

1.69

1.77

1.84

1.81

RA

69.7

71.2

71.6

72.0

73.7

RA=Rheumatoid arthritis; CVD=Cardiovascular disease; ASHD=Arteriosclerotic Heart Disease;

CHF=Congestive heart failure; CVA/TIA=Cerebrovascular Accidents/Transient Ischemic Attack;

PVD=peripheral artery disease; NAFLD=Non-alcoholic fatty liver disease


Conclusion: Hypertension, CVD, hyperlipidemia, diabetes, anemia, and cancer are common in RA patients. Other inflammatory conditions increased over the years studied. Further analysis should evaluate the effect of RA treatment and of secondary prevention in patients with other inflammatory conditions.


Disclosure: S. Li, None; J. T. Molony, None; Y. Peng, None; K. M. Nieman, None; D. T. Gilbertson, None.

To cite this abstract in AMA style:

Li S, Molony JT, Peng Y, Nieman KM, Gilbertson DT. Prevalence of Rheumatoid Arthritis and Associated Comorbidities in the 2011-2015 Medicare Population [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-rheumatoid-arthritis-and-associated-comorbidities-in-the-2011-2015-medicare-population/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2017

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-rheumatoid-arthritis-and-associated-comorbidities-in-the-2011-2015-medicare-population/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology